Emerging immunotherapy strategies in breast cancer

Immunotherapy

Volumn 6, Issue 2, 2014, Pages 195-209

  Page, David B ^a   Naidoo, Jarushka ^a   McArthur, Heather L ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

adoptive therapy; breast cancer; immunotherapy; ipilimumab; nivolumab; trastuzumab; tremelimumab

Indexed keywords

ANIMALS; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOTHERAPY;

EID: 84893855017     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.13.166     Document Type: Review

References (105)

1. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711-723 (2010).
2. Robert C, Thomas L, Bondarenko I et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364(26), 2517-2526 (2011).
3. Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363(5), 411-422 (2010).
4. Hudis CA. Trastuzumab-mechanism of action and use in clinical practice. N. Engl. J. Med. 357(1), 39-51 (2007). (Pubitemid 47026733)
5. Varchetta S, Gibelli N, Oliviero B et al. Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2. Cancer Res. 67(24), 11991-11999 (2007).
6. Beano A, Signorino E, Evangelista A et al. Correlation between NK function and response to trastuzumab in metastatic breast cancer patients. J. Transl. Med. 6, 25 (2008).
7. Arnould L, Gelly M, Penault-Llorca F et al. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br. J. Cancer 94(2), 259-267 (2006). (Pubitemid 43151545)
8. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat. Med. 6(4), 443-446 (2000). (Pubitemid 30208162)
9. Musolino A, Naldi N, Bortesi B et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J. Clin. Oncol. 26(11), 1789-1796 (2008).
10. Diessner J, Bruttel V, Becker K et al. Targeting breast cancer stem cells with HER2-specific antibodies and natural killer cells. Am. J. Cancer Res. 3(2), 211-220 (2013).
11. Park S, Jiang Z, Mortenson ED et al. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell 18(2), 160-170 (2010).
12. Knutson KL, Perez EA, Ballman KV et al. Generation of adaptive HER2-specific immunity in HER2 breast cancer patients by addition of trastuzumab to chemotherapy in the adjuvant setting: NCCTG (Alliance) study N9831. J. Clin. Oncol. 31(Suppl. 15), Abstract 522 (2013).
13. Clynes R, Knutson KL, Ballman KV et al. Combination trastuzumab and chemotherapy to induce immunity to multiple tumor antigens in patients with HER2-positive metastatic breast cancer: NCCTG (Alliance) studies N0337 and N98-32-52. J. Clin. Oncol. 31(Suppl. 15), Abstract 521 (2013).
14. Carson WE, Parihar R, Lindemann MJ et al. Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells. Eur. J. Immunol. 31(10), 3016-3025 (2001). (Pubitemid 32994553)
15. Jaime-Ramirez AC, Mundy-Bosse BL, Kondadasula S et al. IL-12 enhances the antitumor actions of trastuzumab via NK cell IFN-gamma production. J. Immunol. 186(6), 3401-3409 (2011).
16. Repka T, Chiorean EG, Gay J. et al. Trastuzumab and interleukin-2 in HER2-positive metastatic breast cancer: a pilot study. Clin. Cancer Res. 9(7), 2440-2446 (2003). (Pubitemid 36842083)
17. Mani A, Roda J, Young D et al. A Phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab. Breast Cancer Res. Treat. 117(1), 83-89 (2009).
18. Nelson BH. IL-2, regulatory T cells, and tolerance. J. Immunol. 172(7), 3983-3988 (2004). (Pubitemid 38375208)
19. Parihar R, Nadella P, Lewis A et al. A Phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: analysis of sustained interferon gamma production in a subset of patients. Clin. Cancer Res. 10(15), 5027-5037 (2004). (Pubitemid 39099777)
20. Bekaii-Saab TS, Roda JM, Guenterberg KD et al. A Phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies. Mol. Cancer Ther. 8(11), 2983-2991 (2009).
21. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344(11), 783-792 (2001). (Pubitemid 32222155)
22. Gianni L, Pienkowski T, Im YH et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, Phase 2 trial. Lancet Oncol. 13(1), 25-32 (2012).
23. Verma S, Miles D, Gianni L et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N. Engl. J. Med. 367(19), 1783-1791 (2012).
24. Jain R, Rawat A, Verma B, Markiewski MM, Weidanz JA. Antitumor activity of a monoclonal antibody targeting major histocompatibility complex class I-Her2 peptide complexes. J. Natl Cancer Inst. 105(3), 202-218 (2013).
25. Lander ES, Linton LM, Birren B et al. Initial sequencing and analysis of the human genome. Nature 409(6822), 860-921 (2001). (Pubitemid 32165345)
26. Wang-Johanning F, Radvanyi L, Rycaj K et al. Human endogenous retrovirus K triggers an antigen-specific immune response in breast cancer patients. Cancer Res. 68(14), 5869-5877 (2008).
27. Wang-Johanning F, Rycaj K, Plummer JB et al. Immunotherapeutic potential of anti-human endogenous retrovirus-K envelope protein antibodies in targeting breast tumors. J. Natl Cancer Inst. 104(3), 189-210 (2012).
28. Coley WB. The treatment of inoperable sarcoma by bacterial toxins (the mixed toxins of the Streptococcus erysipelas and the Bacillus prodigiosus). Proc. R. Soc. Med. 3(Surg Sect), 1-48 (1910).
29. Disis ML, Knutson KL, Schiffman K, Rinn K, Mcneel DG. Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer. Breast Cancer Res. Treat. 62(3), 245-252 (2000).
30. Emens LA. Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade. Expert Rev. Anticancer Ther. 12(12), 1597-1611 (2012).
31. Milani A, Sangiolo D, Montemurro F, Aglietta M, Valabrega G. Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives. Ann. Oncol. 24(7), 1740-1748 (2013).
32. Mittendorf EA, Clifton GT, Holmes JP et al. Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer 118(10), 2594-2602 (2012).
33. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat. Rev. Immunol. 8(1), 59-73 (2008).
34. Chen G, Emens LA. Chemoimmunotherapy: reengineering tumor immunity. Cancer Immunol. Immunother. 62(2), 203-216 (2013).
35. Gasser S, Orsulic S, Brown EJ, Raulet DH. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 436(7054), 1186-1190 (2005). (Pubitemid 41232299)
36. Apetoh L, Ghiringhelli F, Tesniere A et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 13(9), 1050-1059 (2007). (Pubitemid 47517504)
37. Emens LA, Asquith JM, Leatherman JM et al. Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation. J. Clin. Oncol. 27(35), 5911-5918 (2009).
38. Kimura T, Finn OJ. MUC1 immunotherapy is here to stay. Expert Opin. Biol. Ther. 13(1), 35-49 (2013).
39. Rakha EA, Boyce RW, Abd El-Rehim D et al. Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer. Mod. Pathol. 18(10), 1295-1304 (2005). (Pubitemid 41348648)
40. von Mensdorff-Pouilly S, Verstraeten AA, Kenemans P et al. Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin. J. Clin. Oncol. 18(3), 574-583 (2000). (Pubitemid 30078538)
41. Blixt O, Bueti D, Burford B et al. Autoantibodies to aberrantly glycosylated MUC1 in early stage breast cancer are associated with a better prognosis. Breast Cancer Res. 13(2), R25 (2011).
42. Apostolopoulos V, Pietersz GA, Tsibanis A et al. Pilot Phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835]. Breast Cancer Res. 8(3), R27 (2006).
43. Mohebtash M, Tsang KY, Madan RA et al. A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer. Clin. Cancer Res. 17(22), 7164-7173 (2011).
44. Lakshminarayanan V, Thompson P, Wolfert MA et al. Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine. Proc. Natl Acad. Sci. USA 109(1), 261-266 (2012).
45. Scanlan MJ, Gure AO, Jungbluth AA, Old LJ, Chen YT. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol. Rev. 188, 22-32 (2002). (Pubitemid 35398862)
46. Grigoriadis A, Caballero OL, Hoek KS et al. CT-X antigen expression in human breast cancer. Proc. Natl Acad. Sci. USA 106(32), 13493-13498 (2009).
47. Hamai A, Duperrier-Amouriaux K, Pignon P et al. Antibody responses to NY-ESO-1 in primary breast cancer identify a subtype target for immunotherapy. PLoS ONE 6(6), e21129 (2011).
48. Balafoutas D, Zur Hausen A, Mayer S et al. Cancer testis antigens and NY-BR-1 expression in primary breast cancer: prognostic and therapeutic implications. BMC Cancer 13, 271 (2013).
49. Hamai A, Memeo L, Colarossi C et al. Expression of MAGE-A antigens is frequent in triple-negative breast cancers but does not correlate with that of basal-like markers. Ann. Oncol. 22(4), 986-987 (2011).
50. Ademuyiwa FO, Bshara W, Attwood K et al. NY-ESO-1 cancer testis antigen demonstrates high immunogenicity in triple-negative breast cancer. PLoS ONE 7(6), e38783 (2012).
51. Theurillat JP, Ingold F, Frei C et al. NY-ESO-1 protein expression in primary breast carcinoma and metastases: correlation with CD8+ T-cell and CD79a+ plasmacytic/B-cell infiltration. Int. J. Cancer 120(11), 2411-2417 (2007). (Pubitemid 46642128)
52. Yuan J, Gnjatic S, Li H et al. CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc. Natl Acad. Sci. USA 105(51), 20410-20415 (2008).
53. Theurillat JP, Zurrer-Hardi U, Varga Z et al. Distinct expression patterns of the immunogenic differentiation antigen NY-BR-1 in normal breast, testis and their malignant counterparts. Int J. Cancer 122(7), 1585-1591 (2008). (Pubitemid 351294967)
54. Met O, Balslev E, Flyger H, Svane IM. High immunogenic potential of p53 mRNA-transfected dendritic cells in patients with primary breast cancer. Breast Cancer Res. Treat. 125(2), 395-406 (2011).
55. Svane IM, Pedersen AE, Johansen JS et al. Vaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; monitoring of serum YKL-40 and IL-6 as response biomarkers. Cancer Immunol. Immunother. 56(9), 1485-1499 (2007). (Pubitemid 47024713)
56. Soliman HH, Minton SE, Han HS et al. A Phase I study of ad.p53 DC vaccine in combination with indoximod in metastatic solid tumors. Presented at: 2013 American Society of Clinical Oncology Annual Meeting. Chicago, IL, USA, 31 May-4 June 2013 (Abstract 3069).
57. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12(4), 252-264 (2012).
58. Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J. Exp. Med. 182(2), 459-465 (1995).
59. Vonderheide RH, Lorusso PM, Khalil M et al. Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells. Clin. Cancer Res. 16(13), 3485-3494 (2010).
60. Mauriac L, Romieu G, Bines J. Activity of fulvestrant versus exemestane in advanced breast cancer patients with or without visceral metastases: data from the EFECT trial. Breast Cancer Res. Treat. 117(1), 69-75 (2009).
61. Brignone C, Escudier B, Grygar C, Marcu M, Triebel F. A Phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma. Clin. Cancer Res. 15(19), 6225-6231 (2009).
62. Brignone C, Grygar C, Marcu M, Schakel K, Triebel F. A soluble form of lymphocyte activation gene-3 (IMP321) induces activation of a large range of human effector cytotoxic cells. J. Immunol. 179(6), 4202-4211 (2007).
63. Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr. Opin. Immunol. 24(2), 207-212 (2012).
64. Dong H, Strome SE, Salomao DR et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8(8), 793-800 (2002).
65. Sznol M, Kluger HM, Hodi FS et al. Survival and long-term follow-up of safety and response in patients (pts) with advanced melanoma (MEL) in a Phase I trial of nivolumab (anti-PD-1; BMS-936558; ONO-4538). Presented at: 2013 American Society of Clinical Oncology Annual Meeting. Chicago, IL, USA, 31 May-4 June 2013 (Abstract CRA9006).
66. Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc. Natl Acad. Sci. USA 107(9), 4275-4280 (2010).
67. Wolchok J, Kluger HM, Callahan M, Postow MA. Safety and clinical activity of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in combination with ipilimumab in patients (pts) with advanced melanoma (MEL). Presented at: 2013 American Society of Clinical Oncology Annual Meeting. Chicago, IL, USA, 31 May-4 June 2013 (Abstract 9012).
68. Ghebeh H, Mohammed S, Al-Omair A et al. The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia 8(3), 190-198 (2006). (Pubitemid 43671234)
69. Grosso JF, Horak CE, Inzunza D, Cardona DM, Simon JS. Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients (pts) with advanced solid tumors treated with nivolumab (anti-PD-1; BMS-936558; ONO-4538). Presented at: 2013 American Society of Clinical Oncology Annual Meeting. Chicago, IL, 31 May-4 June 2013 (Suppl.; Abstract 3016).
70. Ge Y, Xi H, Ju S, Zhang X. Blockade of PD-1/PD-L1 immune checkpoint during DC vaccination induces potent protective immunity against breast cancer in hu-SCID mice. Cancer Lett. 336(2), 253-259 (2013).
71. Stagg J, Loi S, Divisekera U et al. Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc. Natl Acad. Sci. USA 108(17), 7142-7147 (2011).
72. Kohrt HE, Houot R, Weiskopf K et al. Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. J. Clin. Invest. 122(3), 1066-1075 (2012).
73. Revicki DA, van den Eertwegh AJ, Lorigan P et al. Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment. Health Qual. Life Outcomes 10, 66 (2012).
74. Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J. Clin. Oncol. 30(21), 2691-2697 (2012).
75. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366(26), 2443-2454 (2012).
76. Weber JS, Dummer R, De Pril V, Lebbe C, Hodi FS, Investigators MDX. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a Phase 3 trial in patients with advanced melanoma. Cancer 119(9), 1675-1682 (2013).
77. Shiao SL, Coussens LM. The tumor-immune microenvironment and response to radiation therapy. J. Mammary Gland Biol. Neoplasia 15(4), 411-421 (2010).
78. Demaria S, Kawashima N, Yang AM et al. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin. Cancer Res. 11(2 Pt 1), 728-734 (2005). (Pubitemid 40116901)
79. Matsumura S, Wang B, Kawashima N et al. Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells. J. Immunol. 181(5), 3099-3107 (2008).
80. Dewan MZ, Galloway AE, Kawashima N et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin. Cancer Res. 15(17), 5379-5388 (2009).
81. Verbrugge I, Hagekyriakou J, Sharp LL et al. Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies. Cancer Res. 72(13), 3163-3174 (2012).
82. Barth A, Wanek LA, Morton DL. Prognostic factors in 1,521 melanoma patients with distant metastases. J. Am. Coll. Surg. 181(3), 193-201 (1995).
83. Kiess AP, Wolchok J, Barker CA et al. Ipilimumab and sterotactic radiosurgery for melanoma brain metastases. Presented at: 54th Annual Meeting of the American Society for Radiation Oncology. Boston, MA, USA, 28-31 October 2012 (Abstract 287).
84. Barker CA, Postow MA, Khan SA et al. Concurrent radiotherapy and ipilimumab immunotherapy for patients with melanoma. Cancer Immunol. Res. 1, 92-98 (2013).
85. Knisely JP, Yu JB, Flanigan J, Sznol M, Kluger HM, Chiang VL. Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. J. Neurosurg. 117(2), 227-233 (2012).
86. Shoukat S, Marcus DM, Rizzo M, Lawson DH, Liu Y, Khan MK. Outcome with stereotactic radiosurgery (SRS) and ipilimumab (Ipi) for malignant melanoma brain metastases. Presented at: 2013 American Society of Clinical Oncology Annual Meeting. Chicago, IL, USA 31 May-4 June 2013 (Abstract 3032).
87. Slovin SF, Higano CS, Hamid O et al. Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter Phase I/II study. Ann. Oncol. 24(7), 1813-1821 (2013).
88. Postow MA, Callahan MK, Barker CA et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N. Engl. J. Med. 366(10), 925-931 (2012).
89. Melero I, Hirschhorn-Cymerman D, Morales-Kastresana A, Sanmamed MF, Wolchok JD. Agonist antibodies to TNFR molecules that costimulate T and NK cells. Clin. Cancer Res. 19(5), 1044-1053 (2013).
90. Sabel MS. Cryo-immunology: a review of the literature and proposed mechanisms for stimulatory versus suppressive immune responses. Cryobiology 58(1), 1-11 (2009).
91. Noguchi M, Earashi M, Fujii H, Yokoyama K, Harada K, Tsuneyama K. Radiofrequency ablation of small breast cancer followed by surgical resection. J. Surg. Oncol. 93(2), 120-128 (2006). (Pubitemid 43235257)
92. Waitz R, Solomon SB, Petre EN et al. Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy. Cancer Res. 72(2), 430-439 (2012).
93. Diab A, Solomon SB, Comstock C et al. A pilot study of preoperative (pre-op), single-dose ipilimumab (ipi) and/or cryoablation (cryo) in women (pts) with early-stage/resectable breast cancer (ESBC). Presented at: 2013 American Society of Clinical Oncology Breast Cancer Symposium. San Francisco, CA, USA, 7-9 September 2013 (Poster P4-13-01).
94. Hersh EM, O'Day SJ, Powderly J et al. A Phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naive patients with advanced melanoma. Invest. New Drugs 29(3), 489-498 (2011).
95. Di Giacomo AM, Ascierto PA, Pilla L et al. Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm Phase 2 trial. Lancet Oncol. 13(9), 879-886 (2012).
96. Small EJ, Higano CS, Tchekmedyian NS et al. Randomized Phase II study comparing 4 monthly doses of ipilimumab (MDX-010) as a single agent or in combination with a single dose of docetaxel in patients with hormone-refractory prostate cancer. Presented at: 2006 American Society of Clinical Oncology Annual Meeting. Atlanta, GA, USA 2-6 June (Suppl.; Abstract 4609) 2006.
97. Reck M, Bondarenko I, Luft A et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter Phase 2 trial. Ann. Oncol. 24(1), 75-83 (2013).
98. Lynch TJ, Bondarenko I, Luft A et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter Phase II study. J. Clin. Oncol. 30(17), 2046-2054 (2012).
99. Rizvi NA, Antonia SJ, Quan Man Chow L et al. A Phase I study of nivolumab (anti-PD-1; BMS-936558, ONO-4358) plus platinum-based doublet chemotherapy (PT-doublet) in chemotherapy-naive non-small cell lung cancer (NSCLC) patients (pts). Presented at: 2013 American Society of Clinical Oncology Annual Meeting. Chicago, IL, USA, 31 May-4 June 2013 (Abstract 8072).
100. Lee F, Jure-Kunkel MN, Salvati ME. Synergistic activity of ixabepilone plus other anticancer agents: preclinical and clinical evidence. Ther. Adv. Med. Oncol. 3(1), 11-25 (2011).
101. Wolchok JD, Kluger H, Callahan MK et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369(2), 122-133 (2013).
102. Waitz R, Fasso M, Allison JP. CTLA-4 blockade synergizes with cryoablation to mediate tumor rejection. Oncoimmunology 1(4), 544-546 (2012).
103. Brentjens RJ, Davila ML, Riviere I et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci. Transl. Med. 5(177), 177ra138 (2013).
104. Tamada K, Geng D, Sakoda Y et al. Redirecting gene-modified T cells toward various cancer types using tagged antibodies. Clin. Cancer Res. 18(23), 6436-6445 (2012).
105. Wilkie S, Van Schalkwyk MC, Hobbs S et al. Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling. J. Clin. Oncol. 32(5), 1059-1070 (2012).